Merck to acquire Verona Pharma for $10 billion - Finance news and analysis from Global Banking & Finance Review
Finance

Merck to acquire Verona Pharma for $10 billion

Published by Global Banking & Finance Review

Posted on July 9, 2025

1 min read

· Last updated: July 9, 2025

Add as preferred source on Google

Merck Acquires Verona Pharma for $10 Billion to Enhance Respiratory Portfolio

(Reuters) -Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of its blockbuster cancer drug.

(Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila)

Key Takeaways

  • Merck to acquire Verona Pharma for $10 billion.
  • The acquisition strengthens Merck's respiratory treatment portfolio.
  • Verona Pharma is UK-based.
  • Merck prepares for patent expiry of a key cancer drug.
  • Deal enhances Merck's global pharmaceutical presence.

Frequently Asked Questions

What is the value of Merck's acquisition of Verona Pharma?
Merck will acquire Verona Pharma for approximately $10 billion.
Why is Merck acquiring Verona Pharma?
The acquisition is aimed at strengthening Merck's presence in respiratory treatments.
Where is Verona Pharma based?
Verona Pharma is based in the UK.
Who reported on the acquisition?
The acquisition was reported by Reuters.
What market is Merck preparing for with this acquisition?
Merck is preparing for the patent expiration in the respiratory treatment market.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category